Business Description
Sartorius Stedim Biotech SA
NAICS : 334517
SIC : 3842
ISIN : FR0013154002
Total Employee Number:
10,456Compare
Compare
Traded in other countries / regions
DIM.FranceSRTOY.USA0RG8.UK56S1.GermanyDIM.AustriaDIM N.Mexico IPO Date
2021-08-16Description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | 2.79 | |||||
Interest Coverage | 4.55 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.79 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7 | |||||
3-Year EBITDA Growth Rate | -16.1 | |||||
3-Year EPS without NRI Growth Rate | -30.4 | |||||
3-Year FCF Growth Rate | 15.9 | |||||
3-Year Book Growth Rate | 16.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.46 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.16 | |||||
Quick Ratio | 0.55 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 155.86 | |||||
Days Sales Outstanding | 29.23 | |||||
Days Payable | 65.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.33 | |||||
3-Year Dividend Growth Rate | -18.2 | |||||
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 2.61 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.87 | |||||
Operating Margin % | 19.05 | |||||
Net Margin % | 9.74 | |||||
EBITDA Margin % | 28.63 | |||||
FCF Margin % | 13.12 | |||||
OCF Margin % | 26.36 | |||||
ROE % | 7.15 | |||||
ROA % | 3.63 | |||||
ROIC % | 5.49 | |||||
3-Year ROIIC % | -14.1 | |||||
ROC (Joel Greenblatt) % | 24.17 | |||||
ROCE % | 7.93 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 55.4 | |||||
Forward PE Ratio | 43.01 | |||||
PE Ratio without NRI | 55.4 | |||||
Shiller PE Ratio | 40.7 | |||||
Price-to-Owner-Earnings | 60.07 | |||||
PEG Ratio | 50.36 | |||||
PS Ratio | 5.4 | |||||
PB Ratio | 3.84 | |||||
Price-to-Free-Cash-Flow | 41.11 | |||||
Price-to-Operating-Cash-Flow | 20.56 | |||||
EV-to-EBIT | 34.47 | |||||
EV-to-Forward-EBIT | 41.12 | |||||
EV-to-EBITDA | 21.52 | |||||
EV-to-Forward-EBITDA | 26.48 | |||||
EV-to-Revenue | 6.16 | |||||
EV-to-Forward-Revenue | 9.5 | |||||
EV-to-FCF | 46.94 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 2.53 | |||||
Price-to-DCF (Earnings Based) | 5.78 | |||||
Price-to-DCF (FCF Based) | 1.36 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Earnings Yield (Greenblatt) % | 2.9 | |||||
FCF Yield % | 2.42 | |||||
Forward Rate of Return (Yacktman) % | -4.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sartorius Stedim Biotech SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 62,620.418 | ||
| EPS (TTM) (MXN) | 43.377 | ||
| Beta | 0.0419 | ||
| 3-Year Sharpe Ratio | -1.24 | ||
| 3-Year Sortino Ratio | -1.18 | ||
| Volatility % | 0.33 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 4374.26 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 4374.26 - 4374.26 | ||
| Shares Outstanding (Mil) | 97.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sartorius Stedim Biotech SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sartorius Stedim Biotech SA Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-22 | In 89 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 89 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 | 4,374.26 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 4,374.26 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 14:00 | 4,374.26 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 4,374.26 (+0.00%) | ||
| EUR 0.690000 Cash Dividend | 2026-04-01 | 4,374.26 (+0.00%) | ||
| General meeting for 2025 | 2026-03-26 | 4,374.26 (+0.00%) | ||
| Annual report for 2025 | 2026-02-16 | 4,374.26 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-10-16 | 4,374.26 (+0.00%) |
Show
Entries
Sartorius Stedim Biotech SA Frequently Asked Questions
What is Sartorius Stedim Biotech SA(MEX:DIM N)'s stock price today?
The current price of MEX:DIM N is MXN4374.26. The 52 week high of MEX:DIM N is MXN4374.26 and 52 week low is MXN4374.26.
When is next earnings date of Sartorius Stedim Biotech SA(MEX:DIM N)?
The next earnings date of Sartorius Stedim Biotech SA(MEX:DIM N) is 2026-10-22.
Does Sartorius Stedim Biotech SA(MEX:DIM N) pay dividends? If so, how much?
Sartorius Stedim Biotech SA(MEX:DIM N) does not pay dividend.
Press Release
Articles on Sartorius Stedim Biotech SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers